Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Stomach Neoplasms 7Esophageal Neoplasms 4Gastrointestinal Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Adenocarcinoma 2Solid Tumor 1Rectal Neoplasms 1Patients With Advanced or Metastatic Solid Tumors 1Pathologic Complete Response 1Neoplasms, Unknown Primary 1Nasopharyngeal Carcinoma 1Locally Advanced Gastric Adenocarcinoma 1Hand-Foot Syndrome 1Colorectal Neoplasms 1Colonic Neoplasms 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 127Gemcitabine 71Radiotherapy, Intensity-Modulated 61toripalimab 39Capecitabine 37Docetaxel 36Fluorouracil 35Radiotherapy 24camrelizumab 23Drug Therapy 22nimotuzumab 18spartalizumab 13pembrolizumab 13nedaplatin 12Chemoradiotherapy 12sintilimab 11apatinib 11Induction Chemotherapy 11Immune Checkpoint Inhibitors 11tislelizumab 10Nivolumab 10Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiation 9Cetuximab 9Carboplatin 9endostar protein 8Paclitaxel 8Bevacizumab 8anlotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × tegafur-gimeracil-oteracil × Clear all
NCT03904225 2021-06-23

Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis

Zhejiang Cancer Hospital

Phase 2 Unknown
220 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡